

## CURRICULUM VITAE:

Name Edwin P.M. Jansen, MD PhD  
Date of birth March 7<sup>th</sup> 1966  
Professional address Netherlands Cancer Institute/  
Antoni van Leeuwenhoek hospital  
Dept. of Radiotherapy  
Plesmanlaan 121  
1066 CX Amsterdam  
the Netherlands  
e-mail epm.jansen@nki.nl

### Education:

1978-1984 Gymnasium-β, St. Dominicus College, Nijmegen.  
1984-1985 Propaedeuse Chemistry, faculty of Mathematics and Physics, Radboud University, Nijmegen.  
1985-1986 Propaedeuse Health Sciences, faculty of Medicine, Radboud University, Nijmegen.  
1986-1990 Doctoral exam Medicine, faculty of Medicine, Radboud University, Nijmegen.  
1990-1992 Junior residencies  
Sept. 1992 MD (*Cum Laude*), faculty of Medicine, Radboud University, Nijmegen.  
April 14<sup>th</sup> 2010 PhD Thesis (Chemoradiotherapy in Gastric Cancer), Free University, Amsterdam

### Professional experience:

Sept.1992-April 1994 resident *not in training*, diverse departments  
May 1994-Apr.1999 Resident, dept. of Radiotherapy, Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital, Amsterdam (head: H. Bartelink, MD PhD).  
May 1999-Febr.2000 Radiation Oncologist (staff), dept. of Radiotherapy, Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital, Amsterdam  
March 2000-Febr.'02 Radiation Oncologist (staff), dept. of Radiotherapy, Academic Hospital, Free University, Amsterdam.  
March '02-today Radiation Oncologist (staff), dept. of Radiotherapy, Netherlands Cancer Institute/ Antoni van Leeuwenhoek hospital, Amsterdam.  
2015-today (Chair) Board of the Medical Staff, Netherlands Cancer Institute

### Other activities:

2003-2011 Member of the Protocol Review Board of the Netherlands Cancer Institute.  
2003-2010 Member (and 2009-2010 chair) of the Gastrointestinal Tumor working group of the Comprehensive Cancer Center Amsterdam (IKA).  
2011- Member of the board of the Dutch Gastric Cancer Group

### References:

- 1: Claassen YHM, Hartgrink HH, de Steur WO, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenborg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Impact of upfrontrandomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial. *Gastric Cancer*. 2018 Sep 20. doi:10.1007/s10120-018-0875-1. [Epub ahead of print]
- 2: Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. *BMC Cancer*. 2018 Sep 10;18(1):877.
- 3: Claassen YHM, van Amelsfoort RM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Boot H, Trip AK, Jansen EPM, Kranenborg EM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results from the CRITICS Trial. *Ann Surg*. 2018 Jul 10. doi: 10.1097/SLA.0000000000002940. [Epub ahead of print]
- 4: Claassen YHM, van Sandick JW, Hartgrink HH, Dikken JL, De Steur WO, van Grieken NCT, Boot H, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenborg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial. *Br J Surg*. 2018 May;105(6):728-735.
- 5: Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordmark M, Meershoek-Klein Kranenborg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomized phase 3 trial. *Lancet Oncol*. 2018 May;19(5):616-628.

- 6: Claassen YHM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenburg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial. *Eur J Surg Oncol.* 2018 May;44(5):613-619.
- 7: Ho VKY, Jansen EPM, Wijnhoven BPL, Neelis KJ, van Sandick JW, Verhoeven RHA, Lemmens VEP, van Laarhoven HWM. Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. *Ann Surg Oncol.* 2017 Nov;24(12):3647-3657.
- 8: Claassen YHM, de Steur WO, Hartgrink HH, Dikken JL, van Sandick JW, van Grieken NCT, Cats A, Trip AK, Jansen EPM, Kranenburg WMM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH. Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. *Ann Surg.* 2018 Dec;268(6):1008-1013.
- 9: van der Kaaij RT, Snaebjornsson P, Voncken FE, van Dieren JM, Jansen EP, Sikorska K, Cats A, van Sandick JW. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma. *Eur J Cancer.* 2017 May;76:27-35.
- 10: Trip AK, Sikorska K, van Sandick JW, Heeg M, Cats A, Boot H, Jansen EP, Verheij M. Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer. *Radiother Oncol.* 2015 Aug;116(2):239-44.
- 11: Trip AK, Stiekema J, Visser O, Dikken JL, Cats A, Boot H, van Sandick JW, Jansen EP, Verheij M. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study. *Acta Oncol.* 2015 Nov;54(10):1754-62.
- 12: Trip AK, Nijkamp J, van Tinteren H, Cats A, Boot H, Jansen EP, Verheij M. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. *Radiother Oncol.* 2014 Aug;112(2):289-94.
- 13: Stiekema J, Trip AK, Jansen EP, Aarts MJ, Boot H, Cats A, Ponz OB, Gradowska PL, Verheij M, van Sandick JW. Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study. *Ann Surg Oncol.* 2015 Feb;22(2):581-8.
- 14: Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, Plukker JT, Richel DJ, Hulshof MC, van Sandick JW, Cats A, Jansen EP, Hospers GA. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. *Radiother Oncol.* 2014 Aug;112(2):284-8.
- 15: Dikken JL, Coit DG, Baser RE, Gönen M, Goodman KA, Brennan MF, Jansen EP, Boot H, van de Velde CJ, Cats A, Verheij M. Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy. *Int J Radiat Oncol Biol Phys.* 2014 Mar 1;88(3):624-9.
- 16: Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, Verheij M, van Sandick JW. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. *Ann Surg Oncol.* 2014 Apr;21(4):1107-14.
- 17: Kruis MF, van de Kamer JB, Sonke JJ, Jansen EP, van Herk M. Registration accuracy and image quality of time averaged mid-position CT scans for liver SBRT. *Radiother Oncol.* 2013 Dec;109(3):404-8.
- 18: Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, Hauptmann M, van Sandick JW. Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach? *Eur J Surg Oncol.* 2013 Jul;39(7):686-93.
- 19: Jansen EP, Boot H, van de Velde CJ, van Sandick J, Cats A, Verheij M. Can adjuvant chemoradiotherapy replace extended lymph node dissection in gastric cancer? *Recent Results Cancer Res.* 2012;196:229-40.
- 20: Lutz MP, Zalberg JR, Ducreux M, Ajani JA, Allum W, Aust D, Bang YJ, Cascinu S, Hölscher A, Jankowski J, Jansen EP, Kisslich R, Lordick F, Mariette C, Moehler M, Oyama T, Roth A, Rueschoff J, Ruhstaller T, Seruca R, Stahl M, Sterzing F, van Cutsem E, van der Gaast A, van Lanschot J, Ychou M, Otto F; First St Gallen EORTC Gastrointestinal Cancer Conference 2012 Expert Panel. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. *Eur J Cancer.* 2012 Nov;48(16):2941-53.
- 21: Dikken JL, Verheij M, Cats A, Jansen EP, Hartgrink HH, van de Velde CJ. Extended lymph node dissection for gastric cancer from a European perspective. *Gastric Cancer.* 2011 Oct;14(4):396-8.
- 22: Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, Boot H, van Grieken NC, van de Velde CJ, Verheij M, Cats A. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). *BMC Cancer.* 2011 Aug 2;11:329.
- 23: Courrech Staal EF, Aleman BM, van Velthuysen ML, Cats A, Boot H, Jansen EP, van Coevorden F, van Sandick JW. Chemoradiation for esophageal cancer: institutional experience with three different regimens. *Am J Clin Oncol.* 2011 Aug;34(4):343-9.
- 24: Dikken JL, Jansen EP, Cats A, Bakker B, Hartgrink HH, Kranenburg EM, Boot H, Putter H, Peeters KC, van de Velde CJ, Verheij M. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. *J Clin Oncol.* 2010 May 10;28(14):2430-6.
- 25: Jansen EP, Nijkamp J, Gubanski M, Lind PA, Verheij M. Interobserver variation of clinical target volume delineation in gastric

cancer. *Int J Radiat Oncol Biol Phys*. 2010 Jul 15;77(4):1166-70.

26: Jansen EP, Boot H, Dubbelman R, Verheij M, Cats A. Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. *Ann Oncol*. 2010 Mar;21(3):530-4.

27: Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ. Gastric cancer. *Lancet*. 2009 Aug 8;374(9688):477-90.

28: Jansen EP, Boot H, Dubbelman R, Bartelink H, Cats A, Verheij M. Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. *Br J Cancer*. 2007 Sep 17;97(6):712-6.

29: Jansen EP, Boot H, Saunders MP, Crosby TD, Dubbelman R, Bartelink H, Verheij M, Cats A. A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys*. 2007 Dec 1;69(5):1424-8.

30: Hospers GA, Punt CJ, Tesselaar ME, Cats A, Havenga K, Leer JW, Marijnen CA, Jansen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. *Ann Surg Oncol*. 2007 Oct;14(10):2773-9.

31: den Dulk M, Verheij M, Cats A, Jansen EP, Hartgrink HH, Van de Velde CJ. The essentials of locoregional control in the treatment of gastric cancer. *Scand J Surg*. 2006;95(4):236-42. Review.

32: Jansen EP, Saunders MP, Boot H, Oppedijk V, Dubbelman R, Porritt B, Cats A, Stroom J, Valdés Olmos R, Bartelink H, Verheij M. Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. *Int J Radiat Oncol Biol Phys*. 2007 Mar 1;67(3):781-5.

33: Boot H, Jansen EP, Cats A. Treatment of gastric cancer. *N Engl J Med*. 2006 Sep 28;355(13):1387; author reply 1387-8.

34: Jansen EP, Boot H, Verheij M, van de Velde CJ. Optimal locoregional treatment in gastric cancer. *J Clin Oncol*. 2005 Jul 10;23(20):4509-17. Review.

35: Jansen EP, Boot H, Cats A, van Coevorden F, Zoetmulder FA, Verheij M. [New insights in the adjuvant treatment of gastric cancer]. *Ned Tijdschr Geneesk*. 2004 Dec 18;148(51):2529-34. Review. Dutch.

36: Pieters BR, Hart AA, Russell NS, Jansen EP, Peterse JL, Borger J, Rutgers EJ. A comparison in cosmetic outcome between per-operative interstitial breast implants and delayed interstitial breast implants after external beam radiotherapy. *Radiother Oncol*. 2003 May;67(2):159-64.

37: Hurkmans CW, Borger JH, Pieters BR, Russell NS, Jansen EP, Mijnheer BJ. Variability in target volume delineation on CT scans of the breast. *Int J Radiat Oncol Biol Phys*. 2001 Aug 1;50(5):1366-72.

38: Jansen EP, Dewit LG, van Herk M, Bartelink H. Target volumes in radiotherapy for high-grade malignant glioma of the brain. *Radiother Oncol*. 2000 Aug;56(2):151-6. Review.

39: Jansen EP, Keus RB, Hilgers FJ, Haas RL, Tan IB, Bartelink H. Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? *Int J Radiat Oncol Biol Phys*. 2000 Aug 1;48(1):27-35.

40: Nijhuis JG, Bauland CG, Jansen EP, Eskes TK. [Prolonged pregnancy and management: what is on time?]. *Ned Tijdschr Geneesk*. 1990 Sep 15;134(37):1786-9. Review. Dutch.

41: Jansen EP, Wagener DJ, Oosterhof GO. [Gynecomastia in testicular tumors]. *Ned Tijdschr Geneesk*. 1990 Sep 8;134(36):1745-8. Dutch. Erratum in: *Ned Tijdschr Geneesk* 1990 Sep 29;134(39):1928.

#### BOOK (CHAPTERS):

**Jansen E.P.M.**, Verheij M. Diffuse gastric cancer. Radiotherapy (pp 164-166) in: *Gastrointestinal Oncology. A critical multidisciplinary team approach*. Jankowski J, Sampliner R, Kerr D, Fong Y (eds) Blackwell Publishing, Malden (MA) 2008